Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 5/2021

Open Access 01-05-2021 | Breast Cancer | Breast Oncology

Can We Reliably Identify the Pathological Outcomes of Neoadjuvant Chemotherapy in Patients with Breast Cancer? Development and Validation of a Logistic Regression Nomogram Based on Preoperative Factors

Authors: Jian Zhang, MD, Linhai Xiao, MD, Shengyu Pu, MD, Yang Liu, MD, Jianjun He, MD, Ke Wang, MD

Published in: Annals of Surgical Oncology | Issue 5/2021

Login to get access

Abstract

Background

Pathological responses of neoadjuvant chemotherapy (NCT) are associated with survival outcomes in patients with breast cancer. Previous studies constructed models using out-of-date variables to predict pathological outcomes, and lacked external validation, making them unsuitable to guide current clinical practice.

Objective

The aim of this study was to develop and validate a nomogram to predict the objective remission rate (ORR) of NCT based on pretreatment clinicopathological variables.

Methods

Data from 110 patients with breast cancer who received NCT were used to establish and calibrate a nomogram for pathological outcomes based on multivariate logistic regression. The predictive performance of this model was further validated using a second cohort of 55 patients with breast cancer. Discrimination of the prediction model was assessed using an area under the receiver operating characteristic curve (AUC), and calibration was assessed using calibration plots. The diagnostic odds ratio (DOR) was calculated to further evaluate the performance of the nomogram and determine the optimal cut-off value.

Results

The final multivariate regression model included age, NCT cycles, estrogen receptor, human epidermal growth factor receptor 2 (HER2), and lymphovascular invasion. A nomogram was developed as a graphical representation of the model and showed good calibration and discrimination in both sets (an AUC of 0.864 and 0.750 for the training and validation cohorts, respectively). Finally, according to the Youden index and DORs, we assigned an optimal ORR cut-off value of 0.646.

Conclusion

We developed a nomogram to predict the ORR of NCT in patients with breast cancer. Using the nomogram, for patients who are operable and whose ORR is < 0.646, we believe that the benefits of NCT are limited and these patients can be treated directly using surgery.
Literature
1.
Siegel RL, Miller KD. Cancer statistics, 2020. CA: A Cancer J. Clin. 2020;70(1):7–30.
2.
Golshan M, Cirrincione CT, Sikov WM, et al. Impact of neoadjuvant chemotherapy in stage II–III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance). Ann Surg. 2015;262(3):434.PubMedPubMedCentral
3.
Generali D, Ardine M, Strina C, et al. Neoadjuvant treatment approach: the Rosetta stone for breast cancer? J Natl Cancer Inst Monogr. 2015;2015(51):32–5.PubMed
4.
Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164–72.PubMed
5.
Tanioka M, Hirokaga K, Kitao A, et al. The clinical significance of pathologic complete response using different definitions after neoadjuvant chemotherapy in HER2 positive breast cancer patients according to hormonal receptor status. Cancer Res. 2012;72(24 Suppl):P6-07-30-P06-07-30.
6.
Hurvitz SA, Martin M, Symmans WF, et al. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2018;19(1):115–26.PubMed
7.
Neoadjuvant pembrolizumab takes on TNBC. Cancer Discov. 2019;9(10):Of4.
8.
Takada M, Sugimoto M, Ohno S, et al. Predictions of the pathological response to neoadjuvant chemotherapy in patients with primary breast cancer using a data mining technique. Breast Cancer Res Treat. 2012;134(2):661–70.PubMed
9.
Colleoni M, Viale G, Zahrieh D, et al. Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy. Ann Oncol. 2008;19(3):465–72.PubMed
10.
Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22(8):1736–47.PubMedPubMedCentral
11.
Zhang F, Huang M, Zhou H, et al. A Nomogram to predict the pathologic complete response of neoadjuvant chemotherapy in triple-negative breast cancer based on simple laboratory indicators. Ann Surg Oncol. 2019;26(12):3912–9.PubMed
12.
Fujii T, Kogawa T, Wu J, et al. Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy. Br J Cancer. 2017;116(4):509–14.PubMedPubMedCentral
13.
Zhang F, Zheng W, Ying L, et al. A nomogram to predict brain metastases of resected non-small cell lung cancer patients. Ann Surg Oncol. 2016;23(9):3033–9.PubMed
14.
Colleoni M, Bagnardi V, Rotmensz N, et al. A nomogram based on the expression of Ki-67, steroid hormone receptors status and number of chemotherapy courses to predict pathological complete remission after preoperative chemotherapy for breast cancer. Eur J Cancer. 2010;46(12):2216–24.PubMed
15.
Lu C-H, Liu C-T, Chang P-H, et al. Develop and validation a nomogram to predict the recurrent probability in patients with major salivary gland cancer. J Cancer. 2017;8(12):2247.PubMedPubMedCentral
16.
Liang W, Zhang L, Jiang G, et al. Development and validation of a nomogram for predicting survival in patients with resected non–small-cell lung cancer. J Clin Oncol. 2015;33(8):861–9.PubMed
17.
National Comprehensive Cancer Network. NCCN clinical practice guidelines: breast cancer, version 4. 2017. National Comprehensive Cancer Network; 2018.
18.
Hammond MEH, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med. 2010;134(7):e48–72.PubMed
19.
Wolff AC, Hammond MEH, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007;131(1):18–43.PubMed
20.
Dowsett M, Nielsen TO, A’Hern R, et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst. 2011;103(22):1656–64.PubMedPubMedCentral
21.
Goldhirsch A, Winer EP, Coates A, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013;24(9):2206–23.PubMedPubMedCentral
22.
Ogston KN, Miller ID, Payne S, et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast. 2003;12(5):320–7.PubMed
23.
Rouzier R, Pusztai L, Delaloge S, et al. Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. J Clin Oncol. 2005;23(33):8331–9.PubMed
24.
Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15(4):361–87.PubMed
25.
Hosmer DW Jr, Lemeshow S, Sturdivant RX. Applied logistic regression, vol 398. Wiley, Hoboken; 2013.
26.
Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PMM. The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol. 2003;56(11):1129–35.PubMed
27.
Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3(1):32–5.PubMed
28.
Zhang F, Huang M, Zhou H, Chen K, Jin J, Wu Y, et al. A Nomogram to Predict the Pathologic Complete Response of Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Based on Simple Laboratory Indicators. Ann Surg Oncol. 2019;26(12):3912–19.PubMed
29.
Jung YY, Hyun CL, Jin MS, et al. Histomorphological factors predicting the response to neoadjuvant chemotherapy in triple-negative breast cancer. J Breast Cancer. 2016;19(3):261–7.PubMedPubMedCentral
30.
Li Z, Zhang Y, Zhang Z, Zhao Z, Lv Q. A four-gene signature predicts the efficacy of paclitaxel-based neoadjuvant therapy in human epidermal growth factor receptor 2-negative breast cancer. J Cell Biochem. 2019;120(4):6046–56.PubMed
31.
Liu Z, Li Z, Qu J, Zhang R, Zhou X, Li L. Radiomics of multi-parametric MRI for pretreatment prediction of pathological complete response to neoadjuvant chemotherapy in breast cancer: a multicenter study. Clin Cancer Res. 2019;25(12):3538–47PubMed
32.
Baumgartner A, Tausch C, Hosch S, et al. Ultrasound-based prediction of pathologic response to neoadjuvant chemotherapy in breast cancer patients. Breast. 2018;39:19–23.PubMed
33.
Alvarado R, Yi M, Le-Petross H, et al. The role for sentinel lymph node dissection after neoadjuvant chemotherapy in patients who present with node-positive breast cancer. Ann Surg Oncol. 2012;19(10):3177–84.PubMed
34.
Koolen BB, Valdés Olmos RA, Wesseling J, Vogel WV, Vincent AD, Gilhuijs KGA, et al., Early Assessment of Axillary Response with 18F-FDG PET/CT during Neoadjuvant Chemotherapy in Stage II–III Breast Cancer: Implications for Surgical Management of the Axilla. Ann Surg Oncol. 2013;20(7):2227–35PubMed
35.
Liu C, Jiang Y, Gu X, Xu Z, et al. Predicting level 2 axillary lymph node metastasis in a Chinese breast cancer population post-neoadjuvant chemotherapy: Development and assessment of a new predictive nomogram. Oncotarget. 2017;8(45)79147–56.PubMedPubMedCentral
36.
Gianni L, Pienkowski T, Im Y-H, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(1):25–32.PubMed
37.
Shao Z, Pang D, Yang H, et al. Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia: The PEONY Phase 3 Randomized Clinical Trial. JAMA oncology. 2020;6(3):e193692.PubMed
38.
Masuda N, Lee SJ, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376(22):2147–59.PubMed
39.
Schneeweiss A, Chia S, Hickish T, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013;24(9):2278–84.PubMed
40.
Caudle AS, Gonzalez-Angulo AM, Hunt KK, et al. Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010;28(11):1821–8.PubMedPubMedCentral
41.
Jin X, Jiang Y-Z, Chen S, Shao Z-M, Di G-H. A nomogram for predicting the pathological response of axillary lymph node metastasis in breast cancer patients. Sci Rep. 2016;6(1):32585.PubMedPubMedCentral
42.
Masuda N, Lee SJ, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376(22):2147–59.PubMed
43.
von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380(7):617–28.
44.
Pease AM, Riba LA, Gruner RA, Tung NM, James TA. Oncotype DX® recurrence score as a predictor of response to neoadjuvant chemotherapy. Ann Surg Oncol. 2019;26(2):366–71.PubMed
45.
Soran A, Bhargava R, Johnson R, et al. The impact of Oncotype DX® recurrence score of paraffin-embedded core biopsy tissues in predicting response to neoadjuvant chemotherapy in women with breast cancer. Breast Dis. 2016;36(2-3):65–71.PubMed
46.
Lee AHS, Pinder SE, Macmillan RD, et al. Prognostic value of lymphovascular invasion in women with lymph node negative invasive breast carcinoma. Eur J Cancer. 2006;42(3):357–62.PubMed
47.
Uematsu T, Kasami M, Watanabe J, et al. Is lymphovascular invasion degree one of the important factors to predict neoadjuvant chemotherapy efficacy in breast cancer? Breast Cancer. 2011;18(4):309–13.PubMed
48.
Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer. 1983;31(1):13–20.PubMed
49.
Denkert C, Loibl S, Müller BM, et al. Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial. Ann Oncol. 2013;24(11):2786–93.PubMed
Metadata
Title
Can We Reliably Identify the Pathological Outcomes of Neoadjuvant Chemotherapy in Patients with Breast Cancer? Development and Validation of a Logistic Regression Nomogram Based on Preoperative Factors
Authors
Jian Zhang, MD
Linhai Xiao, MD
Shengyu Pu, MD
Yang Liu, MD
Jianjun He, MD
Ke Wang, MD
Publication date
01-05-2021
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 5/2021
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-020-09214-x

Other articles of this Issue 5/2021

Annals of Surgical Oncology 5/2021 Go to the issue

ASO Author Reflections

ASO Author Reflections: What is the Cost-Effective Treatment of Melanoma Patients with a Positive Sentinel Node?

ASO Author Reflections

ASO Author Reflection: Viruses, the Lung, and Thoracic Neoplasms: Breaking Bad

ASO Author Reflections

ASO Author Reflections: Preoperative Selection of cT4b Esophageal Cancer Patients Who Benefit From a Salvage Robot-Assisted Minimally Invasive Esophagectomy (RAMIE)

Breast Oncology

A Cost-Utility Analysis Comparing Immediate Oncoplastic Surgery with Delayed Oncoplastic Surgery in Smoking Breast Cancer Patients

Breast Oncology

Bilateral Disease Common Among Slovenian CHEK2-Positive Breast Cancer Patients

ASO Author Reflections

ASO Author Reflections: Improving Our Understanding of Socioeconomic Disparities in Cancer Treatment and Outcomes